Periodontitis, Treatment Adherence
Conditions
Keywords
Smad, Periodontitis, Gingival crevicular fluid, Saliva
Brief summary
Recently, it has been stated that Smads play an active role in all conditions where transforming growth factor-beta (TGF-β) is involved, including periodontal inflammation. This study aimed to examine the levels of TGF-β and inhibitor Smads in saliva and gingival crevicular fluid (GCF) in patients with Stage 3 Grade B periodontitis before and after non-surgical periodontal treatment. Twenty (20) stage 3 grade B periodontitis and 20 periodontally healthy individuals were included in the study. Clinical periodontal measurements were recorded; periodontitis patients received non-surgical periodontal treatment, and GCF and saliva samples were obtained at baseline and one month after treatment. TGF-β, Smad6, and Smad7 were determined by ELISA.
Interventions
DIAGNOSTIC_TESTPeriodontally healthy group
probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium
DIAGNOSTIC_TESTPeriodontitis
: interdental clinical attachment level (CAL) ≥ 5 mm and PPD ≥ 6 mm on at least two non-adjacent teeth, bone loss involving the middle or apical third of the root radiographically, moderate ridge defect and ≥30% of teeth
Sponsors
Bulent Ecevit University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
25 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Have at least 20 natural teeth, excluding third molars. * Periodontitis patients had at least two non-adjacent sites per quadrant with probing depth (PD) ≥ 5 mm and clinical attachment level (CAL) ≥ 5 mm with gingival inflammation, and alveolar bone loss affecting \>30% of the teeth, as detected on clinical and radiographical examinations. * Periodontally healthy control group had no sign of gingival inflammation, no PD \> 3mm and no evidence of attachment or bone loss
Exclusion criteria
* History of systemic disease. * Regular use of any drugs which can effect the immune system or inflammatory response in the 6 months preceding the start of the study. * Periodontal treatment during last 6 months that could affect periodontal status. * Smoking. * History of radiotherapy or chemotherapy. * Current pregnancy, lactation or menopause.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| TGF-β, Smad6, and Smad7 levels | baseline | the levels of TGF-β, Smad6, and Smad7 in gingival crevicular fluid (GCF) and saliva |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| TGF-β, Smad6, and Smad7 levels | baseline and 1st month after treatment | the levels of TGF-β, Smad6, and Smad7 in gingival crevicular fluid (GCF) and saliva before and after non-surgical periodontal treatment. |
Countries
Turkey (Türkiye)
Outcome results
None listed